The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | Session highlights: integrating cellular therapy in myeloma
Krina Patel, MD, Msc, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of her presentation at the 2022 IMS meeting, which covered several topics, including how to optimize treatment approaches and patient access to CAR-T therapy, patient eligibility for CAR-T, and issues with manufacturing processes. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
